2018 Medicines in Development for Neurological Disorders

2018 Medicines in Development for Neurological Disorders

A Report on Disorders of the Brain, Spinal Cord and Nerves

Alzheimer's Disease Drug Name

Sponsor

ABBV-8E12 (anti-tau antibody)

AbbVie North Chicago, IL

AC-1204 (glucose stimulant)

Accera Boulder, CO

ACI-24 (anti-Abeta vaccine)

AC Immune Lausanne, Switzerland

ACI-35 (anti-pTau vaccine)

AC Immune Lausanne, Switzerland Janssen Pharmaceuticals Raritan, NJ

aducanumab (BIIB037) (amyloid beta mAb)

Biogen Cambridge, MA Eisai Woodcliff Lake, NJ

AGB101 (levetiracetam low-dose)

AgeneBio Baltimore, MD

Indication

Phase of Development

Alzheimer's disease (see also other)

Phase II

mild to moderate Alzheimer's disease

Phase III

Alzheimer's disease

Phase I

Alzheimer's disease

Phase I

Alzheimer's disease (Fast Track)

Phase III

amnestic mild cognitive impairment in Alzheimer's disease

Phase II completed

Medicines in Development: Neurological Disorders 2018

1

Alzheimer's Disease Drug Name

ALZ-801 (amyloid beta-protein inhibitor)

Sponsor

Alzheon Framingham, MA

ALZT-OP1 (amyloid beta-protein inhibitor/ inflammation mediator inhibitor)

AZTherapies Boston, MA

AMG520 (CNP520) (BACE1 protein inhibitor)

Amgen Thousand Oaks, CA Novartis Pharmaceuticals East Hanover, NJ

ANAVEXTM 2-73 (M1 muscarinic receptor agonist/ intracellular sigma 1 receptor agonist)

Anavex Life Sciences New York, NY

AstroStem mesenchymal stem cell therapy

Nature Cell Seoul, South Korea

AUS-131 (nonhormonal estrogen receptor agonist)

Ausio Pharmaceuticals Cincinnati, OH

Indication

mild Alzheimer's disease (Fast Track) (homozygous APOE4/4 genotype)

mild Alzheimer's disease (heterozygous APOE4 genotype)

Alzheimer's disease

Phase of Development

Phase II

Phase II

Phase III

Alzheimer's disease (Fast Track)

Phase II/III

Alzheimer's disease (see also epilepsy, genetic, Parkinson's)

Phase II

Alzheimer's disease Alzheimer's disease

Phase I/II naturecell.co.kr

Phase I/II

Medicines in Development: Neurological Disorders 2018

2

Alzheimer's Disease Drug Name

AVN-101 (serotonin 6 receptor antagonist)

AVN-322 (serotonin 6 receptor antagonist)

AVP-786 (deudextromethorphan analogue/ ultra-low does quinidine)

AXS-05 (bupropion/dextromethorphan)

azeliragon (TTP488) (RAGE antagonist)

BAN2401 (anti-amyloid beta mAb)

bexarotene (RXR-selective retinoid analogue)

BI 409306 (PDE9A inhibitor)

Sponsor

Indication

Avineuro San Diego, CA

cognition dysfunction associated with Alzheimer's disease

Avineuro San Diego, CA

cognition dysfunction associated with Alzheimer's disease

Avanir Pharmaceuticals Aliso Viejo, CA

agitation in Alzheimer's disease

(Fast Track)

(see also brain injury)

Axsome Therapeutics New York, NY

agitation in Alzheimer's disease

(Fast Track)

vTv Therapeutics High Point, NC

Alzheimer's disease (Fast Track)

Biogen Cambridge, MA Eisai Woodcliff Lake, NJ

Alzheimer's disease

ReXceptor Cambridge, MA

Alzheimer's disease

Boehringer Ingelheim Pharmaceuticals Ridgefield, CT

Alzheimer's disease

Phase of Development

Phase II

Phase II

Phase III

Phase II/III

Phase III

Phase II

Phase I completed

Phase II boehringer-

Medicines in Development: Neurological Disorders 2018

3

Alzheimer's Disease Drug Name

BIIB076 (anti-tau antibody)

BIIB080 (IONIS-MAPTRX) (tau-targeting protein)

BIIB092 (tau protein inhibitor)

BNC375 (positive allosteric modulator)

BPN14770 (type 4 cyclic nucleotide phosphodiesterase inhibitor)

bryostatin 1 (protein kinase C stimulant)

CAD106 (amilomotide) (VLP immunotherapy vaccine)

Sponsor

Biogen Cambridge, MA

Biogen Cambridge, MA Ionis Pharmaceuticals Carlsbad, CA

Biogen Cambridge, MA

Merck Kenilworth, NJ Bionomics Thebarton, Australia

Tetra Discovery Partners Grand Rapids, MI

Neurotrope BioScience New York, NY

Novartis Pharmaceuticals East Hanover, NJ

Indication

Alzheimer's disease

Alzheimer's disease (see also other)

Phase of Development

Phase I

Phase I/II

Alzheimer's disease (see also other)

cognitive dysfunction in Alzheimer's disease

Phase I

Phase I .au

Alzheimer's disease

Phase I

Alzheimer's disease Alzheimer's disease

Phase II

Phase II

Medicines in Development: Neurological Disorders 2018

4

Alzheimer's Disease Drug Name

Sponsor

COR-388 (bacterial protease inhibitor)

Cortexyme South San Francisco, CA

Corplex Donepezil donepezil transdermal patch

Corium International Menlo Park, CA

Corplex Memantine memantine transdermal patch

Corium International Menlo Park, CA

CPC-201 (donepezil/solifenacin)

Allergan Parsippany, NJ Chase Pharmaceuticals Washington, DC

CPC-212 (next-generation acetylcholinesterase inhibitor)

Allergan Parsippany, NJ Chase Pharmaceuticals Washington, DC

CPC-250 (next-generation acetylcholinesterase inhibitor)

Allergan Parsippany, NJ Chase Pharmaceuticals Washington, DC

CSP-1103 (amyloid beta-protein inhibitor)

CereSpir New York, NY

Medicines in Development: Neurological Disorders 2018

Indication

Alzheimer's disease Alzheimer's disease Alzheimer's disease Alzheimer's disease

Phase of Development

Phase I

Phase I

Phase I

Phase II

Alzheimer's disease

Phase I competed

Alzheimer's disease

Phase I competed

mild cognitive impairment in patients at risk for Alzheimer's

Phase II

5

Alzheimer's Disease Drug Name

crenezumab (anti-amyloid beta antibody)

CSTC1 (BAC)

CT1812 (amyloid beta oligomer receptor antagonist)

E2006 (anti-amyloid beta mAb)

E2027 (amyloid beta oligomer receptor antagonist)

E2609 (BACE1 protein inhibitor)

eltoprazine (serotonin 1A/1B receptor agonist)

Sponsor

Genentech South San Francisco, CA

Charsire Biotechnology Tainan, Taiwan

Cognition Therapeutics Pittsburgh, PA

Eisai Woodcliff Lake, NJ Purdue Pharma Stamford, CT

Eisai Woodcliff Lake, NJ

Biogen Cambridge, MA Eisai Woodcliff Lake, NJ

Amarantus BioScience San Francisco, CA

Medicines in Development: Neurological Disorders 2018

Indication

Phase of Development

Alzheimer's disease

Phase III

Alzheimer's disease

Phase II .tw

mild to moderate Alzheimer's disease

(Fast Track)

Phase I

irregular sleep-wake rhythm disorder and Alzheimer's disease

Phase II

Alzheimer's disease

Phase I

early Alzheimer's disease (Fast Track)

Phase III

aggression in Alzheimer's disease (see also Parkinson's)

Phase II

6

Alzheimer's Disease Drug Name

EVT302 (MAO-B inhibitor)

gantenerumab (amyloid beta-protein inhibitor)

GC021109 (purinoceptor P2Y6 agonist)

GRF6019 (plasma infusions)

HSRx-888 (donepezil/food-based compound)

immune globulin/albumin

INP102 (intranasal insulin)

JNJ-54861911 (BACE inhibitor)

JNJ-63733657 (immunomodulator)

Sponsor

Evotec Princeton, NJ

Genentech South San Francisco, CA

GliaCure Boston, MA

Alkahest San Carlos, CA

HSRx Biopharmaceutical Tucson, AZ

Grifols Los Angeles, CA

Impel NeuroPharma Seattle, WA

Janssen Research & Development Raritan, NJ

Janssen Research & Development Raritan, NJ

Medicines in Development: Neurological Disorders 2018

Indication

Phase of Development

Alzheimer's disease

Phase II

Alzheimer's disease

Phase III

Alzheimer's disease

Phase I

mild to moderate Alzheimer's disease

Phase I

Alzheimer's disease

Phase II

Alzheimer's disease

Phase III

Alzheimer's disease

Phase 0

asymptomatic patients (amyloidpositive) at risk for Alzheimer's

Phase II/III

Alzheimer's disease

Phase I

7

Alzheimer's Disease Drug Name

KPAX002 (repurposed methylphenidate)

lanabecestat (BACE inhibitor)

LM11A-31 (p75 neutrophin receptor)

LMTX? tau protein aggregation inhibitor/ TDP-43 aggregation inhibitor

Lu AF20513 (anti beta amyloid)

LY3002813 (N3pG-A? mAb)

LY3202626 (BACE inhibitor)

Sponsor

K-PAX Pharmaceuticals Mill Valley, CA

AstraZeneca Wilmington, DE Eli Lilly Indianapolis, IN

PharmatrophiX Menlo Park, CA

TauRx Pharmaceuticals Singapore

Lundbeck Deerfield, IL Otsuka Pharmaceutical Tokyo, Japan

Eli Lilly Indianapolis, IN

Eli Lilly Indianapolis, IN

Medicines in Development: Neurological Disorders 2018

Indication

Alzheimer's disease (see also ALS, Parkinson's)

Alzheimer's disease (Fast Track)

Phase of Development

in clinical trials

Phase III

mild to moderate Alzheimer's disease

Phase I/II

mild to moderate Alzheimer's disease

Phase III

mild Alzheimer's disease

Phase I

Alzheimer's disease Alzheimer's disease

Phase II

Phase II

8

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download